scholarly journals The causes and frequency of kidney allograft failure in a low-resource setting: Data from Iraqi Kurdistan

2021 ◽  
Author(s):  
Alaa Abbas Ali ◽  
Safaa E Almukhtar ◽  
Kais H Abd ◽  
Zana Sidiq M Saleem ◽  
Dana A Sharif ◽  
...  
Keyword(s):  
Graft Failure ◽  
Interstitial Fibrosis ◽  
Graft Loss ◽  
The United States ◽  
Failure Rates ◽  
Antibody Mediated Rejection ◽  
Iraqi Kurdistan ◽  
Resource Setting ◽  
Long Term Treatment ◽  
One Year

Abstract Background In the developing world, transplantation is the most common long-term treatment for patients with end-stage renal disease, but rates and causes of graft failure are uncertain. Methods In 2019, in Iraqi Kurdistan, 301 of 871 renal transplant patients had indicated graft biopsies. Outcomes were followed over the subsequent year of 2020. Results The post-transplantation time ranged from one day to 18 years. All donors were living. Approximately 15% of transplants were preemptive. Pretransplant hemodialysis (HD) was twice weekly and less than one year. The median recipient age was 39 (IQR 28 to 48) years. 5.5% of recipients had previous transplants; 3.7% had pretransplant donor-specific antibodies (DSA). The Kaplan-Meier estimated graft failure rates for all-cause, return to HD, and death with functional graft (DWFG) were 9.1%, 6.3%, and 2.9% at one year and 23.8%, 6.3%, and 7.4% at five years. The median death-censored graft survival was 15 years. The most frequent biopsy diagnoses associated with graft failure were interstitial fibrosis and tubular atrophy (IF/TA) (23.1%), transplant glomerulopathy (13.7%), and acquired active antibody-mediated rejection (11.1%). The significant predictors of graft loss were C4d + biopsies (P < 0.01) and advanced IF/TA (P < 0.001). Conclusions These Iraqi patients had estimated graft failure rates similar to the United States (US) Renal Data System living-donor outcomes reported for the year 2000. The inability to approach recent US graft survivals may owe to inadequate pretransplant dialysis. Nevertheless, prolonged survival made chronic disorders and acquired DSA the leading causes of graft failure and is creating a need for second transplants.

scholarly journals The causes and frequency of kidney allograft failure in a low-resource setting: observational data from Iraqi Kurdistan

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Alaa Abbas Ali ◽  
Safaa E. Almukhtar ◽  
Kais H. Abd ◽  
Zana Sidiq M. Saleem ◽  
Dana A. Sharif ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Graft Failure ◽  
Graft Loss ◽  
Failure Rates ◽  
Antibody Mediated Rejection ◽  
Transplant Patients ◽  
Iraqi Kurdistan ◽  
Resource Setting ◽  
Long Term Treatment ◽  
Renal Transplant Patients

Abstract Background In the developing world, transplantation is the most common long-term treatment for patients with end-stage renal disease, but rates and causes of graft failure are uncertain. Methods This was a retrospective outcomes study of renal transplant patients seen in Iraqi Kurdistan nephrology clinics in the year 2019. In 2019, 871 renal transplant patients were registered and outcomes followed through 12/31/2020. Indicated renal biopsies were obtained on 431 patients at 1 day to 18 years post-transplantation. Outcomes were compared with United States Renal Data System (USRDS) living donor reports. Results All donors were living. The recipient age was 38.5 ± 13.3 years, 98.2% were < 65 years old, 3.7% had previous transplants, and 2.8% had pretransplant donor-specific antibodies (DSA). Gehan-Breslow estimated failure rates for all-cause, return to HD, and death with functional graft were 6.0, 4.2, and 1.9% at 1 year and 18.1, 13.7, and 5.1% at 5 years post-engraftment (USRDS 2000; 1 year: 7.0, 5.0, 2.6%; 5 year: 22.3, 15.2, 10.6%. USRDS 2010; 1 year: 3.7, 2.4, 1.4%; 5 year: 15.3, 9.6, 7.3%). The median graft survival was 15 years. Acute tubular injury (ATI), infarction, and acute T cell-mediated rejection accounted for 22.2% of graft loss, with > 75% of these failures taking place in the first year. Most graft failures occurred late, at a median post-transplant time of 1125 (interquartile range, 365–2555) days, and consisted of interstitial fibrosis and tubular atrophy (IF/TA) (23.8%), transplant glomerulopathy (13.7%), and acquired active antibody-mediated rejection (12.0%). The significant predictors of graft loss were C4d + biopsies (P < 0.01) and advanced IF/TA (P < 0.001). Conclusions Kurdistan transplant patients had graft failure rates similar to living donors reported by the USRDS for the year 2000 but higher than reported for 2010. Compared to USRDS 2010, Kurdistan patients had a moderate excess of HD failures at one and 5 years post-engraftment. Nevertheless, prolonged survival is the norm, with chronic disorders and acquired DSA being the leading causes of graft loss.

scholarly journals Pretransplant Donor-Specific Anti-HLA Antibodies and the Risk for Rejection-Related Graft Failure of Kidney Allografts

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Michiel G. H. Betjes ◽  
Kasia S. Sablik ◽  
Henny G. Otten ◽  
Dave L. Roelen ◽  
Frans H. Claas ◽  
...  
Keyword(s):  
T Cell ◽  
Graft Survival ◽  
Survival Data ◽  
Graft Failure ◽  
Graft Loss ◽  
Specific Antibodies ◽  
Antibody Mediated Rejection ◽  
Early Graft ◽  
Donor Specific Antibodies ◽  
One Year

Background. The presence of donor-specific antibodies (DSAs) against HLA before kidney transplantation has been variably associated with decreased long-term graft survival. Data on the relation of pretransplant DSA with rejection and cause of graft failure in recipients of donor kidneys are scarce. Methods. Patients transplanted between 1995 and 2005 were included and followed until 2016. Donor-specific antibodies before transplantation were determined retrospectively. For cause, renal transplant biopsies were reviewed. Results. Pretransplant DSAs were found in 160 cases on a total of 734 transplantations (21.8%). In 80.5% of graft failures, a diagnostic renal biopsy was performed. The presence of pretransplant DSA (DSApos) increased the risk of graft failure within the first 3 months after transplantation (5.2% vs. 9.4%) because of rejection with intragraft thrombosis (p<0.01). One year after transplantation, DSApos recipients had an increased hazard for antibody-mediated rejection at 10 years (9% DSAneg vs. 15% DSApos, p=0.01) with significant decreased graft survival at 10 years (79% DSAneg vs. 69% DSApos, p=0.02). This could largely contribute to an increased graft loss because of antibody-mediated rejection in the DSApos group. The incidence and graft loss because of T cell-mediated rejection was not affected by the presence of pretransplant DSA. Conclusions. Pretransplant DSAs are a risk factor for early graft loss and increase the incidence for humoral rejection and graft loss but do not affect the risk for T cell-mediated rejection.

scholarly journals SO031ANGIOTENSIN II TYPE 1 RECEPTOR (AT1R) EXPRESSION IN RENAL TRANSPLANT BIOPSIES AND ANTI-AT1R ANTIBODIES IN SERUM AS AN INDICATOR OF THE RISK OF TRANSPLANT LOSS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Agnieszka Sas-Strózik ◽  
Piotr Donizy ◽  
Katarzyna Kościelska-Kasprzak ◽  
Dorota Kamińska ◽  
Kamila Gawlik ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Graft Loss ◽  
At1 Receptor ◽  
Receptor Expression ◽  
Positive Staining ◽  
Antibody Mediated Rejection ◽  
Peritubular Capillaries ◽  
One Year ◽  
Transplant Biopsy

Abstract Background and Aims The manifestation of anti-angiotensin II type 1 receptor (AT1R) antibodies is considered a risk factor for transplant injury, however, the occurrence of AT1-Receptor expression in renal transplant biopsy may be an additional feature which can help to predict transplant loss. The aim of our study was to evaluate the expression of AT1R together with their antibodies and assess the risk of transplant loss in patients who had a renal transplant indication biopsy. Method AT1-Receptor immunoreactivity was analyzed in renal transplant biopsies. Additionally, we analyzed the presence of anti-AT1R antibodies in these patients using ELISA method. The result of more than 10 was assessed as positive. Immunohistochemical evaluation of AT1-Receptor expression was performed on 4 μm-thick paraffin sections mounted on silanized slides. AT1-Receptor expression was analyzed in five compartments: 1.tubular epithelium, 2.glomeruli, 3.peritubular capillaries, 4.interstitium and 5.renal blood vessels (small and intermediate arteries) based on a 3-step scale. Results We checked 156 samples of biopsies for the immunoreactivity of the AT1-Receptor. In all these patients we were able to access the presence of anti-AT1R antibodies. A group of 67 patients had positive AT1-Receptor expression (R+) and 16 patients had positive anti-AT1R antibodies (R+Ab+) results. A group of 89 patients had no expression of AT1-Receptor (R-), among which 51 had also no anti-AT1R (R-Ab-). One-year post-biopsy graft loss in the R+Ab+ patients was 37% (6/16) compared to 10% (7/69) in the R-Ab- patients (p = 0.006). Two-year and three-year graft loss was 43% vs. 17% (p=0.02) and 50% vs. 21% (p=0.02) respectively. Moreover, six patients had positive staining of AT1-Receptors in microcirculation (glomeruli and peritubular capillaries), which was associated with antibody mediated rejection. Conclusion The presence of anti-AT1R antibodies in serum together with the expression of AT1-Receptor in transplant biopsy was associated with a significantly higher graft loss. The relevance of AT1-Receptor expression analyzed together with anti-AT1R antibodies should be considered for better transplant immunological risk assessment.

Dispelling the myth of Asian homogeneity: Improved outcomes of Chinese Americans after kidney transplantation

2018 ◽  
Vol 3 ◽  
pp. 5-9
Author(s):  
Farah Karipineni ◽  
Afshin Parsikia ◽  
PoNan Chang ◽  
John Pang ◽  
Stalin Campos ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Graft Survival ◽  
Patient Survival ◽  
Graft Loss ◽  
Graft Function ◽  
Chinese Americans ◽  
The United States ◽  
Chinese Patients ◽  
One Year ◽  
Patient And Graft Survival

Objectives: Asians represent the fastest growing ethnic group in the United States. Despite significant diversity within the group, many transplant studies treat Asians as a homogeneous entity. We compared patient and graft survival among major Asian eth- nicities to determine whether any subgroup has superior out- comes. Methods: We conducted a retrospective analysis of kidney trans- plants on Asian and White patients between 2001 and 2012. Co- variates included gender, age, comorbidities, and donor category. Primary outcomes included one-year patient and graft survival. Secondary outcomes included delayed graft function (DGF) and rejection as cause of graft loss and death. Results: Ninety-one Asian patients were identified. Due to the large proportion of Chinese patients (n=37), we grouped other Asians into one entity (n=54) for statistical comparison among Chinese, other Asians, and Whites (n=346). Chinese subjects had significantly lower body mass index (BMI) (p=0.001) and had the lowest proportion of living donors (p>0.001). Patient survival was highest in our Chinese cohort (p>0.001)Discussion: Our study confirms outcome differences among Asian subgroups in kidney transplantation. Chinese demonstrate better patient survival at one year than Whites and non-Chinese Asians despite fewer live donors. Lower BMI scores may partly explain this. Larger, long-term studies are needed to elucidate outcome disparities among Asian subgroups

scholarly journals Aplicação retrospectiva dos escores KDPI e EPTS em pacientes de um Centro de Transplantes Brasileiro / Retrospective application of the KDPI and EPTS scores in patients from a Brazilian Transplant Center

2020 ◽  
Vol 65 (1) ◽  
pp. 1
Author(s):  
Luana Costa de Aguiar ◽  
Bruma Baptista ◽  
Arthur Ferraz Jong Mun Lee ◽  
Filipe Bissoli ◽  
Vinícius Bortoloti Péterle ◽  
...  
Keyword(s):  
Loss Rate ◽  
Graft Loss ◽  
The United States ◽  
Kidney Transplants ◽  
The North ◽  
Kidney Recipients ◽  
Transplant Center ◽  
Deceased Donors ◽  
One Year

Introdução: KDPI e EPTS são escores implantados nos Estados Unidos em 2014 para guiar a alocação de enxertos renais. O objetivo deste trabalho é correlacionar valores desses escores com desfechos dos transplantes renais realizados em um Centro de Transplantes brasileiro, avaliando sua capacidade de predizer prognóstico nesta população. Métodos: Estudo observacional, individuado, longitudinal e retrospectivo com 163 pares receptor-doador de transplantes renais com doadores falecidos, realizados entre 2012 e 2017, com acompanhamento até 2019. Resultados: Pacientes com enxertos de KDPI menor ou igual à mediana obtiveram menor mortalidade após um ano (p = 0,02); menor taxa de perda de enxerto até um ano (p = 0,00) e após um ano (p = 0,03) e menor nível de creatinina (p = 0,00). Receptores com EPTS menor ou igual à mediana obtiveram taxa de perda de enxerto significativamente menor, se comparados aos com valores acima da mediana (p = 0,01). O coeficiente de correlação entre KDPI e EPTS foi da ordem de 0,016 (p = 0,84). Conclusão: O KDPI evidenciou-se como ferramenta objetiva e de fácil aplicação para predizer prognóstico e, assim, direcionar os rins a serem transplantados. O EPTS mostrou caráter promissor para avaliação dos receptores renais. Esses dados podem ser complementados com futuros estudos nacionais para possível validação e implementação dos escores no país. Conclusão: Por fim, observou-se que não houve correlação direta entre os valores de KDPI do enxerto com os valores de EPTS de seus receptores, distanciando-se do que é preconizado pela literatura norte-americana.Palavras Chave: Transplante de rim, Seleção de doadores, Sobrevivência de enxertoABSTRACTIntroduction: KDPI and EPTS are scores implemented in the United States in 2014 to guide the allocation of kidney grafts. The objective of this work is to correlate values of these scores with outcomes of kidney transplants performed in a Brazilian Transplant Center, evaluating their ability to predict prognosis in this population. Methods: Observational, individual, longitudinal and retrospective study with 163 recipient-donor pairs of kidney transplants with deceased donors, carried out between 2012 and 2017, with follow-up until 2019. Results: Patients with grafts with KDPI less than or equal to the median had lower mortality after one year (p = 0.02); lower graft loss rate up to one year (p = 0.00) and after one year (p = 0.03) and lower creatinine level (p = 0.00). Recipients with EPTS less than or equal to the median had a significantly lower graft loss rate, compared to those with values greater than the median (p = 0.01). The correlation coefficient between KDPI and EPTS was of about 0.016 (p = 0.84). Conclusion: KDPI proved to be an objective and easy to apply tool to predict prognosis and, thus, direct the kidneys to be transplanted. EPTS showed a promising character for the evaluation of kidney recipients. These data can be complemented with future national studies for possible validation and implementation of such scores in the country. Conclusion: Finally, it was observed that there was no direct correlation between the KDPI values of grafts and the EPTS values of its recipients, distancing from what is recommended by the North American literature.Keywords: Kidney transplantation, Donor selection, Graft survival

scholarly journals Analysis of Risk Factors for Kidney Retransplant Outcomes Associated with Common Induction Regimens: A Study of over Twelve-Thousand Cases in the United States

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Alfonso H. Santos ◽  
Michael J. Casey ◽  
Karl L. Womer
Keyword(s):  
Risk Factors ◽  
Graft Loss ◽  
Deceased Donor ◽  
The United States ◽  
Patient Death ◽  
Adult Kidney ◽  
Induction Regimen ◽  
Expanded Criteria ◽  
One Year ◽  
Hla Mismatches

We studied registry data of 12,944 adult kidney retransplant recipients categorized by induction regimen received into antithymocyte globulin (ATG) (N = 9120), alemtuzumab (N = 1687), and basiliximab (N = 2137) cohorts. We analyzed risk factors for 1-year acute rejection (AR) and 5-year death-censored graft loss (DCGL) and patient death. Compared with the reference, basiliximab: (1) one-year AR risk was lower with ATG in retransplant recipients of expanded criteria deceased-donor kidneys (HR = 0.56, 95% CI = 0.35–0.91 and HR = 0.54, 95% CI = 0.27–1.08, resp.), while AR risk was lower with alemtuzumab in retransplant recipients with >3 HLA mismatches before transplant (HR = 0.63, 95% CI = 0.44–0.93 and HR = 0.81, 95% CI = 0.63–1.06, resp.); (2) five-year DCGL risk was lower with alemtuzumab, not ATG, in retransplant recipients of African American race (HR = 0.54, 95% CI = 0.34–0.86 and HR = 0.73, 95% CI = 0.51–1.04, resp.) or with pretransplant glomerulonephritis (HR = 0.65, 95% CI = 0.43–0.98 and HR = 0.82, 95% CI = 0.60–1.12, resp.). Therefore, specific risk factor-induction regimen combinations may predict outcomes and this information may help in individualizing induction in retransplant recipients.

Interpreting CD56+ and CD163+ Infiltrates in Early versus Late Renal Transplant Biopsies

2015 ◽  
Vol 41 (4-5) ◽  
pp. 362-369 ◽  
Author(s):  
Sung Shin ◽  
Young Hoon Kim ◽  
Yong Mee Cho ◽  
Yangsoon Park ◽  
Seungbong Han ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Graft Failure ◽  
Interstitial Fibrosis ◽  
Human Kidney ◽  
The Other ◽  
Cell Infiltration ◽  
Tubular Atrophy ◽  
Antibody Mediated Rejection ◽  
Other Hand ◽  
Histologic Lesion

Background: CD56+ and CD163+ cell infiltration in human kidney transplant biopsies have not been fully evaluated. Methods: We investigated the association of CD56+ and CD163+ cell infiltration with human kidney transplant biopsies with antibody- or T-cell-mediated rejection (TCMR) and other histologic lesions. One hundred and seventy four clinically indicated transplant biopsies were included in this analysis. Immunohistochemical staining for C4d, CD56 and CD163 was performed. Results: One hundred and seventy four indication biopsies were divided into early (≤1 year posttransplant; n = 49) and late (>1 year posttransplant; n = 125) biopsies. High numbers of CD56+ cells were uncommon in early biopsies except for those with antibody-mediated rejection (AMR) only. On the other hand, high numbers of CD56+ cells were observed in late biopsies diagnosed as TCMR only, AMR only, and TCMR combined with AMR. In early biopsies, both CD56+ and CD163+ infiltrates correlated strongly with interstitial inflammation, tubulitis, and peritubular capillaritis (ptc) scores. The ci and ct scores, however, were correlated only with the number of CD56+ cells. In late biopsies, on the other hand, the number of CD56+ infiltrates was correlated only with ptc, while the number of CD163+ infiltrates was weakly correlated with any histologic lesion. Multivariable analyses showed that chronic active AMR and the number of CD56+ cells/10 HPF were independently associated with death-censored graft failure post-biopsy. The number of CD163+ cells was not correlated with any pathologic lesion and post-biopsy graft failure. CD56+ infiltrates were also associated with interstitial fibrosis and tubular atrophy. Conclusions: Intragraft CD56+ cell infiltrates were significantly associated with AMR and subsequent poor clinical outcomes.

scholarly journals A Prognostic Tool for Individualized Prediction of Graft Failure Risk within Ten Years after Kidney Transplantation

2019 ◽  
Vol 2019 ◽  
pp. 1-10
Author(s):  
Danko Stamenic ◽  
Annick Rousseau ◽  
Marie Essig ◽  
Philippe Gatault ◽  
Mathias Buchler ◽  
...  
Keyword(s):  
Graft Failure ◽  
Latent Class ◽  
Latent Class Model ◽  
Graft Loss ◽  
Validation Dataset ◽  
Individual Risk ◽  
Kidney Graft ◽  
Failure Risk ◽  
One Year ◽  
The Impact

Identification of patients at risk of kidney graft loss relies on early individual prediction of graft failure. Data from 616 kidney transplant recipients with a follow-up of at least one year were retrospectively studied. A joint latent class model investigating the impact of serum creatinine (Scr) time-trajectories and onset of de novo donor-specific anti-HLA antibody (dnDSA) on graft survival was developed. The capacity of the model to calculate individual predicted probabilities of graft failure over time was evaluated in 80 independent patients. The model classified the patients in three latent classes with significantly different Scr time profiles and different graft survivals. Donor age contributed to explaining latent class membership. In addition to the SCr classes, the other variables retained in the survival model were proteinuria measured one-year after transplantation (HR=2.4, p=0.01), pretransplant non-donor-specific antibodies (HR=3.3, p<0.001), and dnDSA in patient who experienced acute rejection (HR=15.9, p=0.02). In the validation dataset, individual predictions of graft failure risk provided good predictive performances (sensitivity, specificity, and overall accuracy of graft failure prediction at ten years were 77.7%, 95.8%, and 85%, resp.) for the 60 patients who had not developed dnDSA. For patients with dnDSA individual risk of graft failure was not predicted with a so good performance.

scholarly journals The Effect of Posttransplantation Diabetes Mellitus on the Prognosis of Transplantation: a Prospective Cohort Study

2019 ◽  
Author(s):  
Hang Zhou ◽  
Xiaoqian Yang ◽  
Liang Ying ◽  
Xiaodong Yuan ◽  
Yuehan Wei ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Bacterial Infection ◽  
Graft Failure ◽  
Graft Loss ◽  
Graft Function ◽  
Renal Transplant Recipients ◽  
Risk Of Death ◽  
Independent Risk Factors ◽  
One Year

Abstract Background: Posttransplantation diabetes mellitus (PTDM) constitutes one of the most important complications associated with kidney transplantation and is associated with significant morbidity and mortality. Methods: This study was a single-centred prospective observational study that included 310 consecutive renal transplant recipients. The primary end point was graft failure, including death-censored graft failure and mortality. The secondary endpoints include estimated glomerular filtration rate (eGFR) at 12 months and adverse events after transplantation. The prevalence rate of PTDM and relevant risk factors for PTDM were also explored. Results: The incidence of PTDM was 16.4% within one year. Death-censored graft loss rate differed significantly between recipients without PTDM and those with PTDM(0.77% versus 12%, p<0.001). Compared with non-PTDM group, the mean eGFR was significantly lower in the PTDM group(70.55±20.54 ml/min·1.73 m² versus 63.04±21.92 ml/min·1.73 m², P=0.03). Additionally, compared with the other group, the PTDM group was more easily infected by bacteria(16.2% versus 40%, P<0.001). Multi-factor analysis indicated that higher preoperative fasting plasma glucose (FPG), increased age and use of tacrolimus after transplantation were independent risk factors for PTDM. Conclusion: The incidence rate of PTDM is 16.4% 1 year after surgery. Our study suggests that patients with PTDM are at higher risk of death-censored graft loss and bacterial infection, and worse kidney function. Independent risk factors of PTDM include preoperative FPG level, increased age, and tacrolimus. The PTDM group is more vulnerable to worse graft function, postoperative graft loss and bacterial infection.

MO926RAPID VS. LATE RE-TRANSPLANTATION FOR EARLY KIDNEY GRAFT LOSS

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Diana Rodríguez Espinosa ◽  
Jose Jesus Broseta Monzo ◽  
Evelyn Hermida-Lama ◽  
Elena Cuadrado ◽  
Jimena Del Risco ◽  
...  
Keyword(s):  
Graft Survival ◽  
Graft Failure ◽  
Patient Survival ◽  
Statistical Significance ◽  
Graft Loss ◽  
Human Leukocyte ◽  
Type I ◽  
Kidney Graft ◽  
Antibody Mediated Rejection ◽  
Increased Risk

Abstract Background and Aims Early graft failure (EGL) is a devastating complication of kidney transplantation. Patients with EGL have an increased risk of mortality of up to twelve times compared to patients who received grafts that survive beyond 30 days. Moreover, they may have become sensitized to antigens from the failed graft and that human leukocyte antigen antibodies (anti-HLA), identified on single antigen bead assays, may not be reliable until several weeks after transplantation. Thus, if rapid re-transplantation occurs, there is no certainty regarding the recipient's immunological status. Hence, there could be an increased immunological risk with the consequent disturbance of the new graft's survival. Method We performed a retrospective single-center observational study in re-transplanted patients with EGL (defined as graft loss before 30 days from transplant) between January 1977 and November 2019 from our center to analyze the outcomes of rapid re-transplantation (occurred within 30 days of EGL) vs late re-transplantation (occurred beyond those 30 days). Results: T here were 82 re-transplants after EGL. The median overall patient survival after re-transplantation was 32 years. Eight patients died within the first year. Among the mortality causes, there were four septic shocks, one cardiogenic shock, one massive pulmonary thromboembolism, one myocardial infarction, and one unknown cause. When analyzed for periods, death censored graft survival was 89% at one and five years after re-transplantation. One graft was lost at eight days due to antibody-mediated rejection (AMR), while there was one death with a functioning graft three months after re-transplantation secondary to a pulmonary embolism. Seventy-three late re-transplants occurred. When analyzed for periods, death censored graft survival was 81% and 69% at one and five years after re-transplantation, respectively. The median patient survival after late re-transplantation was 32 years. There were fewer deaths after rapid re-transplantation than late re-transplantation, but given the small number of cases in the former, this difference did not reach statistical significance (p = 0.3). There was no association between the timing of re-transplantation and an increased risk of graft failure (HR 0.30 [0.04 – 2.2]). While four rapid re-transplants did not share any incompatibilities between donors, four did share at least one HLA type I incompatibility, and one shared an incompatibility of HLA class I and class II. There were no T-cell mediated rejections (TCMR), and there was only one AMR in the rapid rapid re-transplantation group, whereas there were six TCMRs and fifteen AMRs in the late re-transplantation group (p = 0.03 and p = 0.4, respectively). Conclusion Rapid re-transplantation appears to be safe and does not entail increased rejection risk, nor it diminishes long-term graft survival when compared to late re-transplantation.

Sign in / Sign up

Export Citation Format

Share Document